Formosa Pharmaceuticals Inc. and Almac Discovery Ltd. have announced a global licensing agreement for development and commercialization of ALM-401, a first-in-class engineered bispecific antibody-drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1.
Scientists at University of Connecticut and University of Iowa have described phosphonamidate prodrugs reported to be useful for the treatment of cancer.
Jiangsu Simcere Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker reported to be useful for the treatment of cancer, neurodegeneration, infections, autoimmune and inflammatory disorders.
Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.
Yuhan Corp. has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Prostate cancer remains a significant health concern for men globally, and the search for effective and targeted therapies continues. In a recent study, researchers from Guizhou Medical University identified a new class of 4-trifluoromethylquinoline derivatives that demonstrated potent anti-prostate cancer activity by inhibiting the serum/glucocorticoid-regulated kinase 1 (SGK1).
Protein phosphatase 2A (PP2A) is a key serine/threonine phosphatase that controls various signaling pathways and influences cancer development and treatment outcomes.
Triple-negative breast cancer is an especially challenging subtype characterized by the absence of key receptors, limiting the effectiveness of many standard breast cancer treatments.
RSS
